ATPAF2

Across TCGA pan-cancer cohorts, ATPAF2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ATPAF2 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ATPAF2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ATPAF2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where ATPAF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.947	0.718	.004	15	view →
LSCC	OS	Tertile	All	0.954	0.819	.011	5	view →
CCRCC	OS	Quartile	II,III,IV	1.000	0.070	.036	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ATPAF2–PDAC (OS)

Open the PDAC breakdown →